Get The App!
Loading the player...
Should JAK2V617F Allele Burden Be Monitored in Patients with PV?
Share by Email
Send to social websites
Report this video as inappropriate
You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email.
Select your reason
Violent or Repulsive Content
Hateful or Abusive Content
Harmful Dangerous Acts
Dr. Ruben Mesa, Mayo Clinic, answers the following question: Should JAK2V617F allele burden be monitored in patients with PV?
What Steps Do You Take for Differential Assessment/Treatment of Debilitating Fatigue in Patients wit...
Does Development of HU-Refractory PV Increase a Patient’s Risk for Thrombosis/Cardiovascular Events?...
Would Pregnancy Change the Management of Young Woman with Low-Risk PV? Do You Alter Antithrombotic T...
Should Patients Continue to Receive Anti-Platelet Therapy/Anticoagulation after Progression to Post-...
Does Baseline Platelet Count Determine the Starting Dose of Ruxolitinib for HU-Refractory/Intolerant...
Do You Attempt to Correct Cytopenias Before Giving Ruxolitinib?
Are MF Patients with RBC Transfusion-Dependent Anemia Considered Candidates for Ruxolitinib Therapy?
Do MF Patients with Low Platelets Have a Different Disease Course/Burden Relative to Those with Norm...
Copyright 2020 by NSCI Group, Inc.
On The Go
About MedEd On The Go